stockrow
Saturday 7 November 2026
Export MCRB’s income statement to Excel — free account
Seres Therapeutics, Inc.
MCRB Healthcare Biotechnology
Seres Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $789,000.00, down 99.4% from fiscal 2023.
- Revenue
- +69.0%
- EPS
- −273.6%
- Free cash flow
- −576.7%
Quarter to September 2026, against a year earlier
1.98
0.11
−5.26%
Follow MCRB
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (144.35%) | (66.57%) | (121.87%) | 19.64% |
+8 more TTM periods Free account |
|
| (44.85%) | (18.31%) | (33.29%) | 4.10% | ||
ROIC |
(1,267.77%) | (277.30%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(284.06%) | (79.90%) | (242.41%) | 15.11% | |
Average Days of Receivables |
2,178.49 | 4,899.10 | 55.91 | 128.11 | |
Free Cash Flow per Share |
(6.38) | (5.28) | (4.40) | 0.12 | |
Free Cash Flow |
(63.70) | (51.25) | (42.15) | 1.08 | |
Capital Expenditures |
0.24 | 0.01 | — | (0.04) | |
| Other line items | |||||
Cash ROIC |
(163.81%) | (102.24%) | (74.83%) | 1.19% | |
Accounts Receivable Turnover |
0.32 | 0.14 | 1.02 | 1.14 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,864.09% | 2,476.69% | 3,315.84% | 3,330.62% | |
Selling, General and Administrative Expense of Revenue |
1,323.20% | 1,707.17% | 2,323.34% | 2,658.25% | |
Share Based Compensation of Revenue |
402.96% | 487.84% | 643.46% | 735.91% | |
Operating CF/Net income |
1.36 | 2.28 | 0.90 | 0.20 | |
Depreciation/Fixed assets |
0.96 | 0.59 | 0.56 | 0.54 | |
Capex/Depreciation |
0.08 | 0.00 | 0.00 | (0.01) | |
Revenue per Share |
0.21 | 0.19 | 0.16 | 0.17 | |
Operating CF per Share |
(6.41) | (5.28) | (4.40) | 0.13 | |
Capex per Share |
0.02 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.11) | 0.00 | 0.00 | 0.03 |
Columns are period end dates · fundamentals updated 6 Nov 2026